| Ytd | 4.61% | |
| 1y | 8.31% |
| Open | 51.30 | Prev Close | 51.34 | Low | 51.30 | High | 51.63 | Mkt Cap | 15.76B |
| Vol | 140.20K | Avg Vol | 493.10K | EPS | 2.60 | P/E | 19.85 | Forward P/E | 19.77 |
| Beta | 0.45 | Short Ratio | 13.36 | Inst. Own | 57.43% | Dividend | 2.09 | Div Yield | 4.06 |
| Ex Div Date | 07-31 | Earning | 08-07 | 50-d Avg | 52.85 | 200-d Avg | 51.04 | 1yr Est | 62.50 |
EMA News
Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the
BATON ROUGE, La., Aug. 12, 2026 /PRNewswire/ -- Bernhard Capital Partners ("Bernhard"), an infrastru
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Inc. (TSX/NYSE: EMA) today announced the transaction to
Barclays analyst Michael Lonegan maintains Emera (NYSE:EMA) with a Equal-Weight and lowers the pr
Emera TSE: EMA reported second-quarter adjusted earnings of C$212 million, or C$0.69 per share, as t
Emera (NYSE:EMA) reported quarterly earnings of $0.50 per share which missed the analyst consensus e
Emera (NYSE:EMA) reported quarterly earnings of $0.50 per share which missed the analyst consensus e
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Inc. (“Emera”) (TSX/NYSE: EMA) reported 2026 second qua
[url="]PepGen Inc.[/url] (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next g
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of
PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FD
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Inc. (TSX/NYSE: EMA) today announced it has received fi
Neuronata-R retains conditional approval in South Korea PR Newswire SEOUL, South Korea, July 19, 202
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Series J First Preferred Share quarterly dividend in release
[url="]Niagen Bioscience, Inc.[/url] (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide aden
HALIFAX, Nova Scotia--(BUSINESS WIRE)--On July 13, 2026, the Board of Directors of Emera Inc. (TSX/N
HALIFAX, Nova Scotia--(BUSINESS WIRE)--Today Emera (TSX/NYSE: EMA) announced that it will release it
Johnson and Johnson presents new IMAAVYÂ (nipocalimab-aahu) data at European Academy of Neurology (E
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP)
Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults w
WuXi Biologics' Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 C
New TALVEYÂ (talquetamab-tgvs) plus DARZALEX FASPROÂ (daratumumab and hyaluronidase-fihj) data demon
